Pemigatinib Improves OS in FGFR2-Altered Cholangiocarcinoma
A survival benefit was elicited with the use of pemigatinib when used for patients with previously treated advanced cholangiocarcinoma who had an FGFR2 fusion or rearrangement.
Read More